«Cancers evade immunotherapy by «discarding the evidence» of tumor - specific mutations: Discovery could explain widespread acquired resistance among patients treated with immune checkpoint blockade drugs.» (sciencedaily.com)
In a retrospective analysis of clinical trial data, they found that melanoma patients with highly aneuploid tumors were less likely to benefit from immune checkpoint blockade therapy than patients whose tumors showed fewer chromosomal disruptions. (sciencedaily.com)
A Brief Report published recently in the New England Journal of Medicine detailed two cases of patients treated with combination immune checkpoint blockade for metastatic melanoma who developed myositis, early progressive and refractory cardiac electrical instability, and myocarditis. (cancernetwork.com)